Authors
Latest:
Exploratory analysis identifies blood-based biomarkers that may predict treatment outcomes in urothelial carcinomaThe exploratory analysis may have showcased the benefit of testing for tertiary lymphoid structures.
Latest:
Front-line maintenance with avelumab found efficacious for locally advanced, metastatic mUCThe real-world data were presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Latest:
Expert highlights the latest radiotherapy developments in prostate cancer“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.
Latest:
Physician Burnout: Assessing and addressing its impact on your family“A physician struggling under an unbearable weight of emotions, or going to work feeling like they are enduring emotional trauma can have trickle down emotional effects on family members,” writes physician and US Navy veteran Caitlin Delaney, MD.
Latest:
Ava Saidian, MD, on the need for sexual health assessments in female patients"We only have so much time with our patients, but we want to show them that we support them," says Ava Saidian, MD.
Latest:
Expert gives advice on implementing Aquablation with the HYDROS Robotic System"For urologists that are interested in implementing Aquablation into their armamentarium, I am very envious, because anyone who is going to start doing Aquablation now is going to be using the HYDROS System," says Ravi Munver, MD.
Latest:
Neoadjuvant sacituzumab govitecan shows efficacy but now has uncertain future role in bladder cancerNeoadjuvant therapy with sacituzumab govitecan demonstrated hypothesis generating complete responses following surgery with tolerable toxicity after a protocol amendment requiring a dose reduction and G-CSF prophylaxis for patients with muscle-invasive bladder cancer.
Latest:
Malpractice Consult: Affidavits of merit and why they matterMost states require affidavits for malpractice cases to proceed.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
EP. 4B: The Effect of Leuprolide Formulations on Organizational Management Practices in Metastatic Prostate CancerIn this companion article, Brenda Heath, RN, discusses key challenges related to the use of leuprolide acetate and leuprolide mesylate from an organizational management perspective.
Latest:
Quiz: Testicular trauma in 21-year-oldA 21-year-old male presented to the emergency department for evaluation of testicular pain and swelling 5 days after being struck in the groin.
Latest:
Expert emphasizes significance of physician self-careIf you’re a doctor, your job is to take care of others. But too often, that comes at the expense of taking care of yourself.
Latest:
Future Horizons in PSMA-Targeted Imaging and the Management of Prostate CancerExperts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular RecurrenceDr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
Latest:
A urologist on why the time is right to let go"It is the right time and I have been fortunate to have such great people to work with locally and nationally," a urologist writes.
Latest:
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBCPanelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Latest:
Lisa F. Newcomb, PhD, on active surveillance for prostate cancer"My hope is that the results of our study improve the uptake of active surveillance, further reducing unnecessary treatments, and this, combined with the improving reflex tests, may change the risk-benefit of PSA screening," says Lisa F. Newcomb, PhD.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Male sexual health and reproductive medicine: All that glitters is not gold"With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness," write Navid Leelani, DO, and Scott D. Lundy, MD, PhD.
Latest:
Extended lymphadenectomy yields no additional benefit vs standard procedure for urothelial cancerExtended lymph node dissection during radical cystectomy offered no additional overall survival or disease-free survival benefit vs standard lymph node dissection.
Latest:
Conservative management feasible for uncomplicated renal colic patients with positive urine cultures“Though septic stones are well recognized as a medical emergency, patients with uncomplicated renal colic (without systemic inflammatory responses or renal impairment) and positive urine cultures pose a dilemma in management considerations,” the investigators explained in their abstract.
Latest:
Case review: An incidentally discovered renal massAn expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.
Latest:
2-year data show continued enfortumab vedotin efficacy in cisplatin-ineligible MIBCUpdated findings from cohort H of the EV-103 study showed promising 2-year event-free survival outcomes and favorable antitumor activity with enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.
Latest:
Dr. Goudelocke outlines stand-up urgency in patients with OAB"There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they called stand-up urgency," according to Colin Goudelocke, MD.
Latest:
Olaparib plus abiraterone/prednisone linked with improved PFS in mCRPCThe median PFS was 39 months (95% CI, 22-not reached [NR]) in arm 3 compared with 8.4 months (95% CI, 2.9-17.0) in arm 1 and 14 months (95% CI, 8.4-20.0) in arm 2.
Latest:
Apalutamide combo hits high 2-year RFS rate in prostate cancerTreatment with apalutamide and androgen deprivation therapy led to a 2-year biochemical recurrence-free survival rate of 100% in patients with high-risk, post-prostatectomy prostate cancer.
Latest:
Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK TrialPanelists discuss how recent data from the EMBARK study indicates that in patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) at high risk for biochemical recurrence (BCR), enzalutamide combined with gonadotropin-releasing hormone (GnRH) significantly improves metastasis-free survival compared with monotherapy options, with no new safety signals reported.
Latest:
AHN Cancer Institute, Illumina to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient CareStudy will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient’s cancer, which may influence choice of treatment based on cancer stage and type.
Latest:
Key Challenges in the Administration of Leuprolide for Advanced/Metastatic Prostate CancerIn the second article of the series, Paul Sieber, MD, shares best practices for the administration of leuprolide in patients with advanced/metastatic prostate cancer.
